ArticleScience translational medicine2022
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 5 pooled it
15.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 5 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Conserved hepatic RNA signatures across multiple cohorts reveal novel mechanistic clues for advanced fibrosis in human MASLD.Hepatology communications · 2026Pooled it
- AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review.Gastroenterology · 2026Guideline
- Pharmacological effects of dihydromyricetin in preclinical models of NAFLD: a systematic review and meta-analysis stratified by dose and duration.Frontiers in pharmacology · 2026Pooled it
- Multi-omic network analysis identified betacellulin as a novel target of omega-3 fatty acid attenuation of western diet-induced nonalcoholic steatohepatitis.EMBO molecular medicine · 2023Pooled it
- Pooled it
- Targeted inhibition of inflammatory liver macrophages with a multifunctional nanoparticle ameliorates metabolic dysfunction-associated steatohepatitis.Bioactive materials · 2027Article
- Hepatic neurons and metabolically induced liver dysfunction.Nature reviews. Endocrinology · 2026Review
- SNX3 exacerbates hepatic fibrosis by amplifying TGF-Acta pharmaceutica Sinica. B · 2026Article
- A data-driven framework reconstructs the molecular continuum of human MASLD progression.Nature metabolism · 2026Article
- Loss of long-range co-expression is a common feature in cancer.NPJ systems biology and applications · 2026Article
- ADAR1 Controls Macrophage Scavenging and Lipid-Buffering Programs in Metabolic Tissues.European journal of immunology · 2026Article
- Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- Integrative transcriptomic analysis reveals miR-26a-5p downregulation and a potential predictive gene signature for the progression of metabolic liver disease.Frontiers in cell and developmental biology · 2026Article
- Immune crosstalk in metabolic dysfunction-associated steatotic liver disease: interactions between innate and adaptive immunity.Frontiers in immunology · 2026Review
- Improving risk stratification and detection of early HCC using ultrasound-based deep learning models.JHEP reports : innovation in hepatology · 2025Article
- Genomic medicine in hepatology: mechanisms and liver treatment strategies.Molecular medicine (Cambridge, Mass.) · 2025Review
- Complexity of metabolic dysfunction-associated steatotic liver disease: State of the art review.Journal of the Chinese Medical Association : JCMA · 2025Review
- The crucial function of IDO1 in pulmonary fibrosis: From the perspective of mitochondrial fusion in lung fibroblasts and targeted molecular inhibition.Acta pharmaceutica Sinica. B · 2025Article
- Lipogenesis and MASLD: re-thinking the role of SREBPs.Archives of toxicology · 2025Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 11 institutions in 4 countries.
Naoto FujiwaraDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.ORCID 0000-0002-4109-3421
Naoto KubotaDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.ORCID 0000-0002-1849-5078
Emilie CrouchetInserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, University of Strasbourg and IHU, Pole Hépato-digestif, Strasbourg University Hospitals, Strasbourg 67000, France.
Bhuvaneswari KoneruDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.
Cesia A MarquezDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.ORCID 0000-0003-0538-9740
Arun K JajoriyaDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.ORCID 0000-0002-8101-2374
Gayatri PandaDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.
Tongqi QianDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.
Shijia ZhuDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.ORCID 0000-0002-2368-2361
Nicolas GoossensDivision of Gastroenterology and Hepatology, Geneva University Hospital, Geneva 44041, Switzerland.
Xiaochen WangDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Shuang LiangDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-5250-1494
Zhenyu ZhongDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-9441-7645
Sara LewisDepartment of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-4713-6453
Bachir TaouliDepartment of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-6409-1333
Myron E SchwartzDepartment of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-9113-886X
Maria Isabel FielDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, U.S.ORCID 0000-0002-7314-6313
Amit G SingalDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.ORCID 0000-0002-1172-3971
Jorge A MarreroDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.
Austin J FobarDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-3112-2898
Neehar D ParikhDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-5874-9933
Indu RamanBioCenter Microarray Core Facility, Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0001-8469-3112
Quan-Zhen LiBioCenter Microarray Core Facility, Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Masataka TaguriDepartment of Data Science, School of Data Science, Yokohama City University, Yokohama 236-0027, Japan.
Atsushi OnoDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.ORCID 0000-0002-2482-945X
Hiroshi AikataDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.ORCID 0000-0002-3409-2156
Takashi NakaharaDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.ORCID 0000-0001-7762-4629
Hayato NakagawaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.ORCID 0000-0002-6973-5094
Yuki MatsushitaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Ryosuke TateishiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.ORCID 0000-0003-3021-2517
Kazuhiko KoikeDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Masahiro KobayashiDepartment of Hepatology, Toranomon Hospital, Tokyo 105-0001, Japan.ORCID 0000-0002-6645-860X
Takaaki HigashiDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8555, Japan.
Shigeki NakagawaDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8555, Japan.ORCID 0000-0003-3994-4028
Yo-Ichi YamashitaDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8555, Japan.
Toru BeppuDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8555, Japan.ORCID 0000-0001-9046-0454
Hideo BabaDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8555, Japan.ORCID 0000-0002-3474-2550
Hiromitsu KumadaDepartment of Hepatology, Toranomon Hospital, Tokyo 105-0001, Japan.
Kazuaki ChayamaCollaborative Research Laboratory of Medical Innovation, Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima 734-8551, Japan.ORCID 0000-0002-5530-5341
Thomas F BaumertInserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, University of Strasbourg and IHU, Pole Hépato-digestif, Strasbourg University Hospitals, Strasbourg 67000, France.
Yujin HoshidaDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas , TX 75390, USA.ORCID 0000-0001-9430-1426
The University of Texas Southwestern Medical Center · USKumamoto University · JPThe University of Tokyo · JPHiroshima University · JPIcahn School of Medicine at Mount Sinai · USInserm · FRToranomon Hospital · JPUniversity of Michigan · USUniversity Hospital of Geneva · CHUniversity of Pennsylvania · USYokohama City University · JP
Funding
Trial of Statins for Chemoprevention in Hepatocellular CarcinomaR01CA255621 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, HOSHIDA, YUJIN · 2021 to 2025
$3.6MPrecision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United StatesU01CA230694 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2018 to 2022
$3.5MReverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5MGlycopathology of HCC: identification of the source cells of serum fucosylationU01CA226052 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DRAKE, RICHARD R., HOSHIDA, YUJIN · 2019 to 2023
$2.8MMolecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6MPrecision Screening for Hepatocellular Carcinoma in Patients with CirrhosisR01CA222900 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2018 to 2023
$2.4MDeciphering the Role of dNTP Metabolism in Innate ImmunityR35GM142654 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI ZHONG, ZHENYU · 2021 to 2025
$2.2MEuropean Research Council 101021417European Research Council 671231NCI NIH HHS R01 CA222900NCI NIH HHS R01 CA233794NCI NIH HHS R01 CA255621NCI NIH HHS U01 CA226052NCI NIH HHS U01 CA230694NIDDK NIH HHS R01 DK099558NIGMS NIH HHS R35 GM142654
Abstract
Prediction of hepatocellular carcinoma (HCC) risk is an urgent unmet need in patients with nonalcoholic fatty liver disease (NAFLD). In cohorts of 409 patients with NAFLD from multiple global regions, we defined and validated hepatic transcriptome and serum secretome signatures predictive of long-term HCC risk in patients with NAFLD. A 133-gene signature, prognostic liver signature (PLS)-NAFLD, predicted incident HCC over up to 15 years of longitudinal observation. High-risk PLS-NAFLD was associated with IDO1
Indexed as
Carcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseCD8-Positive T-LymphocytesHumansLiver CirrhosisRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.